Immunotherapy, another critical field in lung adenocarcinoma treatment, has also gained approval for non-small cell lung cancer, including lung adenocarcinoma, with PD-1/PD-L1 inhibitors like nivolumab [7], pembrolizumab [8], atezolizumab [9], and CTLA-4 inhibitors like ipilimumab [10]. Here, CD274 is linked to lung adenocarcinoma.